|
HY-12887-25mg
|
MedChemexpress LLC
|
Piclamilast [CAS 144035-83-6]
|
|
COVID-19-immunoregulation
|
|
|
HY-12887-5mg
|
MedChemexpress LLC
|
Piclamilast [CAS 144035-83-6]
|
|
COVID-19-immunoregulation
|
|
|
HY-12887-50mg
|
MedChemexpress LLC
|
Piclamilast [CAS 144035-83-6]
|
|
COVID-19-immunoregulation
|
|
|
HY-13213-10mg
|
MedChemexpress LLC
|
AM211 [CAS 1175526-27-8]
|
|
COVID-19-immunoregulation
|
|
|
HY-13213-100mg
|
MedChemexpress LLC
|
AM211 [CAS 1175526-27-8]
|
|
COVID-19-immunoregulation
|
|
|
HY-13213-5mg
|
MedChemexpress LLC
|
AM211 [CAS 1175526-27-8]
|
|
COVID-19-immunoregulation
|
|
|
HY-13213-50mg
|
MedChemexpress LLC
|
AM211 [CAS 1175526-27-8]
|
|
COVID-19-immunoregulation
|
|
|
HY-134004-10mg
|
MedChemexpress LLC
|
Pentoxyverine [CAS 77-23-6]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-134004-100mg
|
MedChemexpress LLC
|
Pentoxyverine [CAS 77-23-6]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-134004-25mg
|
MedChemexpress LLC
|
Pentoxyverine [CAS 77-23-6]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-134004-5mg
|
MedChemexpress LLC
|
Pentoxyverine [CAS 77-23-6]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-134004-50mg
|
MedChemexpress LLC
|
Pentoxyverine [CAS 77-23-6]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-13402-10mg
|
MedChemexpress LLC
|
Varespladib [CAS 172732-68-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-13402-100mg
|
MedChemexpress LLC
|
Varespladib [CAS 172732-68-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-13402-25mg
|
MedChemexpress LLC
|
Varespladib [CAS 172732-68-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-13402-5mg
|
MedChemexpress LLC
|
Varespladib [CAS 172732-68-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-13402-50mg
|
MedChemexpress LLC
|
Varespladib [CAS 172732-68-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-13402A-10mg
|
MedChemexpress LLC
|
Varespladib (sodium) [CAS 172733-42-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-13402A-100mg
|
MedChemexpress LLC
|
Varespladib (sodium) [CAS 172733-42-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-13402A-25mg
|
MedChemexpress LLC
|
Varespladib (sodium) [CAS 172733-42-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-13402A-5mg
|
MedChemexpress LLC
|
Varespladib (sodium) [CAS 172733-42-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-13402A-50mg
|
MedChemexpress LLC
|
Varespladib (sodium) [CAS 172733-42-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-13438-10mg
|
MedChemexpress LLC
|
AZD3839 (free base) [CAS 1227163-84-9]
|
|
Cancer-programmed cell death
|
|
|
HY-13438-25mg
|
MedChemexpress LLC
|
AZD3839 (free base) [CAS 1227163-84-9]
|
|
Cancer-programmed cell death
|
|
|
HY-13438-5mg
|
MedChemexpress LLC
|
AZD3839 (free base) [CAS 1227163-84-9]
|
|
Cancer-programmed cell death
|
|
